Lifileucel and Pembrolizumab for the Treatment of Locally Advanced Stage IIIB-D Melanoma
Status:
Not yet recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
This phase I/II trial tests the safety and side effects of lifileucel and pembrolizumab in
treating patients with stage IIIB-D melanoma that has spread to nearby tissue or lymph nodes
(locally advanced). Biological therapies, such as lifileucel, use substances made from living
organisms that may attack specific tumor cells and stop them from growing or kill them.
Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune
system attack the cancer, and may interfere with the ability of tumor cells to grow and
spread. Giving lifileucel and pembrolizumab may make the tumor smaller.